

March 11, 2022

BSE Limited

Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip code: 532531 The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex Bandra (E) Mumbai - 400 051 Scrip code: STAR

Dear Madam/Sir,

Sub: Press Release

Please find attached Press Release issued by the Company titled:

"Strides receives USFDA approval for Colchicine Tablets"

Thanks & Regards,

For Strides Pharma Science Limited,

Manjula Ramamurthy Company Secretary

Manjula R.

Encl. As above



Strides receives USFDA approval for Colchicine Tablets

To be marketed by Strides Pharma Inc. in the US market

Bengaluru, March 11, 2022 – Strides Pharma Science Limited (Strides) today announced that its stepdown wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for *Colchicine Tablets USP, 0.6 mg* from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Colcrys® Tablets, 0.6 mg, of Takeda Pharmaceuticals U.S.A., Inc. (Takeda).

According to IQVIA MAT January 2022 data, the US market for Colchicine Tablets USP, 0.6 mg is approximately ~US\$ 85 Mn. The product will be manufactured at the company's facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.

The company has 271 cumulative ANDA filings with USFDA of which 245 ANDAs have been approved and 26 are pending approval.

About Colchicine Tablets

Colchicine tablets are used for the treatment and prevention of gout. It reduces inflammation which causes pain, swelling and other symptoms of gout. Colchicine tablets are indicated in adults and children four years or older for treatment of familial Mediterranean fever (FMF).

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy along with an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (New York). The Company focusses on "difficult to manufacture" products that are sold in over 100 countries. Additional information is available at the Company's website at www.strides.com

For further information, please contact:

Strides

Badree Komandur

Executive Director - Finance & Group CFO +91 80 6784 0747

Investor Relations

Sandeep Baid: +91 80 6784 0791 Email: Sandeep.baid@strides.com

Corporate Communication

Pallavi Panchmatia: +91 80 6784 0193 pallavi.panchmatia@strides.com

PR Consultancy

Fortuna PR

Boni Mukherjee: +91 9618682208

boni@fortunapr.com

K Srinivas Reddy: +91 90005 27213

srinivas@fortunapr.com

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17, Vashi,

Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta Road,

. Bengaluru – 560 076